Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 01 2025
0mins
Source: PRnewswire
New Treatment Approval: The European Commission has granted marketing authorization for Oczyesa®, a once-monthly subcutaneous octreotide treatment for adults with acromegaly, designed for convenient self-administration using a pre-filled autoinjector pen.
Clinical Benefits: Clinical studies indicate that Oczyesa® provides effective disease control, improves symptoms and quality of life, and shows a higher proportion of patients achieving normalized IGF-1 levels compared to standard treatments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
